TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2102029
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg allopurinol + 20 mg benzbromarone
Study: 2102029
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol only
Study: 28898714
Drug: Continued care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued care (CC) with weekly to monthly phone calls from a diabetes specialist nurse practitioner
Study: 28898714
Drug: Continued care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued care (CC) for insulin-treated patients
Study: 28898714
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) for insulin-treated patients
Study: 17432641
Drug: Triamcinolone and
Normalized name: triamcinolone and antiseptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone and urea cream
Study: 9972900
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FGF injection).
Study: 7919075
Drug: Nurse-administered health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered health checks
Study: 29642075
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate gel
Study: 25178692
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg infusion for two days)
Study: 23565591
Drug: Intensive advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive advice to withdraw overused medication (Group A)
Study: 10743865
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (control)
Study: 1460163
Drug: ECT, fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT, fluoxetine, or amitriptyline
Study: 6229740
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metronidazole suppository, administered 12-hourly starting 48 hours before elective surgery
Study: 6229740
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g metronidazole i.v. over 20 minutes and 1 g suppository at premedication, continued with one suppository 12-hourly
Study: 6229740
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metronidazole suppository, administered 8-hourly starting 24 hours before surgery for high-risk patients
Study: 6229740
Drug: Rectal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal treatment
Study: 30650291
Drug: Longbishu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longbishu Capsule (LBS) placebos combined Doxazosin Mesylate Tablet (DMT)
Study: 30650291
Drug: Longbishu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT)
Study: 30650291
Drug: Longbishu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT) placebos
Study: 24746224
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (BVA + NSAIDs)
Study: 23172029
Drug: lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine/prilocaine cream
Study: 23172029
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM N(G)‐monomethyl‐l‐arginine (l‐NMMA)
Study: 23172029
Drug: fluconazole +
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluconazole + l‐NMMA
Study: 15878759
Drug: Accelerated chemotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated chemotherapy (CT) regimen: 3 cycles of cisplatin and 5-fluorouracil (days 1, 14, and 28) followed by hyperfractionated radiation therapy (RT) (7440 cGy/62 fractions)
Study: 12560354
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg folic acid supplement plus natural diet
Study: 10622750
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 25% albumin
Study: 7791169
Drug: Indomethacin 150
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 150 mg/day (Group A)
Study: 7791169
Drug: Indomethacin 150
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B)
Study: 2289220
Drug: Tulobuterol 40
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol 40 micrograms/kg twice daily
Study: 2289220
Drug: Albuterol 100
Normalized name: ALBUTEROL 100/IPRATRO 20MCG 120D PO INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 100 micrograms/kg three times daily
Study: 7235865
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (B group)
Study: 7235865
Drug: No follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: No follow-up treatment (A group)
Study: 28051319
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (12 weeks, twice a week for 60 minutes, including breathing exercises, yoga pose practice, and supine meditation/relaxation)
Study: 26301241
Drug: Signature CT-based
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signature CT-based implant positioning system
Study: 21372621
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Study: 17133051
Drug: Medication (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (n = 19)
Study: 17133051
Drug: Medication (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (n = 26)
Study: 10972631
Drug: Immediate simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate simvastatin treatment (40 mg/d)
Study: 10972631
Drug: Deferred simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred simvastatin treatment (40 mg/d after 3 months if LDL-C >3.0 mmol/L)
Study: 10972631
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (immediate and deferred simvastatin treatment)
Study: 1574970
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of naloxone 1 microgram kg‐1 h‐1
Study: 4019017
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (30 min of daily self‐selected aerobic activity)
Study: 31320980
Drug: Antioxidant cocktail
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cocktail (AOC) - 1,000 mg vitamin C, 600 IU vitamin E, and 600 mg α-lipoic acid
Study: 26352063
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (3 μg/kg/min)
Study: 26352063
Drug: Medium-dose dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose dopamine (5 μg/kg/min)
Study: 12131261
Drug: Reboxetine 2
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 2 x 4 mg (REB)
Study: 10421596
Drug: Ibutilide fumarate
Normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibutilide fumarate 0.25 mg
Study: 10421596
Drug: Ibutilide fumarate
Normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibutilide fumarate 0.5 mg
Study: 10421596
Drug: Ibutilide fumarate
Normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibutilide fumarate 1.0 mg
Study: 8678066
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment in elderly patients
Study: 8678066
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment in younger patients
Study: 6606554
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (four times 0.5 g/d)
Study: 26589368
Drug: atorvastatin (10mg/day)
Normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin (10mg/day)
Study: 24706353
Drug: Prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic medication (brimonidine and timolol) instilled 5 minutes before injection
Study: 24706353
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic medication
Study: 24706353
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (with and without prophylactic medication)
Study: 20595646
Drug: n‐3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 group (2.5 g/d of n‐3 LCPUFA, with 1.67 g of EPA and 0.83 g of DHA)
Study: 15660732
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg (t.i.d., n = 33)
Study: 15660732
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg (t.i.d.)
Study: 31522849
Drug: Peanut-0 group
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut-0 group (4000 mg peanut protein through to week 104, then discontinued)
Study: 31522849
Drug: Peanut-300 group
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut-300 group (4000 mg peanut protein through to week 104, then 300 mg daily for 52 weeks)
Study: 24344787
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl solution (TFS) 2.7 mg/kg applied 2-4 hours prior to surgery
Study: 24344787
Drug: Oxymorphone hydrochloride
Normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymorphone hydrochloride 0.22 mg/kg administered subcutaneously 2-4 hours prior to surgery and every 6 hours for 90 hours
Study: 19597964
Drug: Treatment Outcome
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Outcome Score (TOS)
Study: 12407029
Drug: i.v. human
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. human albumin administration
Study: 7544439
Drug: Adenoviral vector
Normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vector containing normal CFTR cDNA (doses: 1, 10, 100, 1000)
Study: 7544439
Drug: Adenoviral vector
Normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vector (highest dose)
Study: 7544439
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of adenoviral vector
Study: 367570
Drug: BOPP (4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOPP (4-drug regimen)
Study: 367570
Drug: MOPP (4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP (4-drug regimen)
Study: 367570
Drug: BOP (3-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOP (3-drug regimen)
Study: 367570
Drug: OPP (3-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPP (3-drug regimen)
Study: 367570
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (vinblastine, chlorambucil, or chlorambucil plus monthly vincristine + prednisone)
Study: 367570
Drug: 4-drug programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug programs (BOPP and MOPP)
Study: 28246176
Drug: Intralipid postconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid postconditioning (ILPC) group received an intravenous infusion of 20% intralipid (2 mL/kg) just 10 min before aortic cross‐unclamping
Study: 22998737
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and decreased fasting insulin
Study: 17966842
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy for 5 weeks
Study: 7528485
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d of carbimazole
Study: 7528485
Drug: Minimal dose
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal dose required to obtain euthyroidism (low dose)
Study: 7528485
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (60 mg/d)
Study: 31901245
Drug: Strict glycemic
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glycemic control (target BG 80-120 mg/dL)
Study: 31901245
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (target BG 180-200 mg/dL)
Study: 25219423
Drug: 6-month weekly
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month weekly group intervention plus six monthly maintenance sessions (N=104)
Study: 16532466
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal patch
Study: 3095220
Drug: Lysine aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine aspirin (150, 300, 600 mg)
Study: 3095220
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin (150, 300, 600 mg)
Study: 3095220
Drug: Conventional aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional aspirin (150, 300, 600 mg)
Study: 29705075
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection femoral nerve block (sFNB)
Study: 22402472
Drug: Watermelon extract
Normalized name: watermelon extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon extract supplementation (L‐citrulline/L‐arginine, 6 g daily)
Study: 16476804
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide 60 mg
Study: 16476804
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide 60 mg and midodrine hydrochloride 5 mg
Study: 10988016
Drug: Lovastatin 20-40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20-40 mg daily
Study: 1645103
Drug: Alcohol (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0 to 1.0 g/kg) administered alone
Study: 1645103
Drug: Cocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (4 to 96 mg/70 kg) administered alone
Study: 1645103
Drug: Cocaine and
Normalized name: Cocaine and morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine and alcohol administered in combination
Study: 2409325
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX), adriblastine (ADR), and cyclophosphamide (CP) for 12 months in COSS-77.
Study: 2409325
Drug: Doubled dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubled dose of methotrexate (MTX), cisplatinum (CPL) or bleomycin + CP + dactinomycin (BCD) in addition to MTX and ADR for 8 months in COSS-80.
Study: 29498170
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 mg/day, N = 47)
Study: 29498170
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 mg/day) in T-allele carriers (CT/TT)
Study: 29498170
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in CC genotype group
Study: 27920083
Drug: Bedtime dosing
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dosing (BD) of enalapril (20 mg at bedtime)
Study: 27920083
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing (MD) of enalapril (20 mg in the morning)
Study: 17460336
Drug: CHO+P+A beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+P+A beverage (10 mL/kg body weight)
Study: 17460336
Drug: CHO beverage
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO beverage (10 mL/kg body weight)
Study: 17460336
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with treatment differences
Study: 9669014
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose tranexamic acid (20 mg.kg‐1)
Study: 9669014
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose tranexamic acid (50 mg.kg‐1)
Study: 9669014
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tranexamic acid (100 mg.kg‐1)
Study: 31103972
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and anti-tuberculosis drug
Study: 31103972
Drug: Anti-tuberculosis drug
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis drug
Study: 19506571
Drug: Levetiracetam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (500 mg b.i.d. to a maximum of 1500 mg b.i.d.)
Study: 3028596
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (EVI, PAV, CMC)
Study: 3028596
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (CAV)
Study: 30902701
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of hormonal therapy
Study: 27809724
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser treatment (Group A)
Study: 22088980
Drug: Clopidogrel 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 225 or 300 mg daily
Study: 18781341
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel
Study: 18781341
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or cisplatin
Study: 16046076
Drug: Betablocker (BB)
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betablocker (BB) propranolol 80 mg
Study: 10751736
Drug: Ceftriaxone 100
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 100 mg/kg/day for 1-3 weeks
Study: 2932742
Drug: Secnidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole (2 g single oral dose)
Study: 2932742
Drug: Tetracycline (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (750 mg per day for 5 days) plus Clioquinol (1 g per day)
Study: 30046828
Drug: CER-001, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001, 3 mg/kg, administered as 10 weekly intravenous infusions
Study: 26945658
Drug: Levofloxacin 400
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 400 mg (oral)
Study: 26945658
Drug: Levofloxacin 400
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 400 mg (oral) + Amikacin 200 mg (intravenous)
Study: 24751903
Drug: RBV monotherapy
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV monotherapy
Study: 24751903
Drug: RBV combination
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV combination therapy
Study: 24751903
Drug: PEG‐IFNa/RBV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNa/RBV combination therapy
Study: 22527075
Drug: Azithromycin 300
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 300 mg/day
Study: 20075643
Drug: Desvenlafaxine (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (200-400 mg/d)
Study: 18570573
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube therapy
Study: 11843062
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination therapy (genotype 2b/3a)
Study: 9727760
Drug: Abstracts concluded
Normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS09 Delicious Abstract Melon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstracts concluded that the test treatment was as effective as or better than the control treatment
Study: 9727760
Drug: Abstracts concluded
Normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS09 Delicious Abstract Melon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstracts concluded that the test treatment was not as effective as the control treatment
Study: 25155105
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg on-demand udenafil
Study: 25155105
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg once-daily udenafil